| Project/Area Number |
07457559
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
応用薬理学・医療系薬学
|
|---|
| Research Institution | Jichi Medical School |
|---|
Principal Investigator |
FUJIMURA Akio.MD.PhD. Jichi Medical School, Department of Clinical Pharmacology Professor, 医学部, 教授 (90156901)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAMORI Isamu.MD.PhD. Fukui Medical School, Department of Medicine Professor, 医学部, 教授 (40142278)
MIURA Sadayasu.MD.PhD. Jichi Medical School, Department of Medicine Professor, 医学部, 教授 (60048965)
HARADA Kazuhiro.MD.PhD. Jichi Medical School, Department of Clinical Pharmacology Instructor, 医学部, 講師 (70245059)
|
|---|
| Project Period (FY) |
1995 – 1997
|
| Project Status |
Completed (Fiscal Year 1997)
|
| Budget Amount *help |
¥5,000,000 (Direct Cost: ¥5,000,000)
Fiscal Year 1997: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1996: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1995: ¥2,600,000 (Direct Cost: ¥2,600,000)
|
|---|
| Keywords | atrial natriuretic peptide / enkephalinase inhibitor / sinorphan / cyclosporine / renal protection / 免疫抑制薬 / 腎障害 |
|---|
| Research Abstract |
Nephrotoxixity is the most bothersome adverse effect of cyclosporine A (CyA), an immunosuppressive agent, and can result in irreversible renal damage. The agent is widely used for the treatment of patients with organ transplant. Therefore, it is important that the drug-induced nephrotoxicity be prevented.
In these studies, the effects of sinorphan, an enkephalinase inhibitor, on CyA-induced adverse events including nephrotoxicity and its immunosuppressive action were examined.
The following results were obtained ;
1)Sinorphan protects against the CyA-induced renal damage.
2)Sinorphan prevents the elevation of blood pressure, probably by inhibition of enhanced endothelin production by CyA.
3)Sinorphan does not influence the imunosuppressive action fo CyA.
4)Sinorphan does not alter the CyA concentration in blood.
These results that sinorphan prevents the CyA-induced adverse events without changing the pharmacologic effecfts of CyA.
|
